Recent advances in adenosine receptor antagonist research

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 10, 2001, Pages 1533-1561

  Hess, S ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Adenosine antagonists; Adenosine receptor; Affinity; Selectivity; Structure activity relationships; Subtypes

Indexed keywords

2 (2 HYDROXYETHYL) 1 [3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL)ACRYLOYL]PIPERIDINE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 (3 PHENYLPROPYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 OXO 3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL) 1(6H) PYRIDAZINEBUTYRIC ACID; 8 (2 NOR 1 ADAMANTYL) 1,3 DIPROPYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; AMILORIDE; CAFFEINE; ISTRADEFYLLINE; LIGAND; LUF 5417; LUF 5433; PROPENTOFYLLINE; THEOPHYLLINE; THIADIAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VUF 5472; XANTHINE DERIVATIVE;

ASTHMA; CENTRAL NERVOUS SYSTEM DISEASE; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG POTENCY; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; IN VIVO STUDY; INFLAMMATORY DISEASE; ISCHEMIA; KIDNEY FAILURE; LIPOPHILICITY; NONHUMAN; REVIEW;

EID: 0034750364     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.10.1533     Document Type: Review

References (124)

1. Receptors for purines and pyrimidines
2. 2 receptors: Design of novel purines and nonpurines as selective ligands
3. Adenosine receptors: New opportunities for future drugs
4. 1-Adenosine receptor antagonists
5. 3 adenosine receptor ligands: History and perspectives
6. 1 receptors
7. CPX
8. Solubilities of adenosine antagonists determined by radioreceptor assay
9. Adenosine receptor antagonists: Structures and potential therapeutic applications
10. Comparative pharmacology of human adenosine receptor subtypes - Characterization of stably transfected receptors in CHO cells
11. Adenosine receptors and their ligands
12. Adenosine receptor ligands-recent developments. Part 1. Agonists
13. 2A receptors
14. 1 receptors
15. 1 adenosine receptors stably transfected in Chinese Hamster Ovary cells
16. Research on purines and their receptors comes of age
17. Purinergic and pyrimidinergic receptors as potential drug targets
18. 3 adenosine receptor agonists: An overview
19. The role of receptor structure in determining adenosine receptor activity
20. Insight into adenosine receptor function using antisense and gene knockout approaches
21. 2B receptors: A novel therapeutic target in asthma?
22. 3 receptor and its ligands
23. Adenosine receptors: Targets for future drugs
24. Adenosine receptors: Pharmacology, structure-activity relationships, and therapeutic potential
25. Effects of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a highly selective adenosine receptor antagonist, on force of contraction in guinea-pig atrial and ventricular cardiac prepartions
26. Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX)
27. 1 Adenosine receptors
28. 1-adenosine receptor
29. Synthesis and use of FSCPX, an irreversible adenosine A1 antagonist, as a 'receptor knock-down' tool
30. 1-adenosine receptor antagonists
31. Behavioural despair in mice: A primary screening test for antidepressants
32. The tail suspension test: A new method for screening antidepressants in mice
33. 1 receptor antagonist
34. 1 receptor antagonist with potent diuretic activity
35. 1 receptor antagonists. Synthesis and structure-activity relationships of a novel series of 3-(2-cyclohexenyl -3-oxo-2,3- dihydropyridazin- 6-yl)-2- phenylpyrazolo [1,5-a]pyridines
36. 1-adenosine receptor antagonists
37. 3 adenosine receptor antagonists
38. 1 adenosine receptors and their ligands: Overview and recent developments
39. 1 receptor agonist and a novel pyrimidoindole on membrane properties and neurotransmitter release in rat cortical and hippocampal neurons
40. 1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays
41. High-pressure synthesis of enantiomerically pure C-6 substituted pyrazolo[3,4-d]pyrimidines
42. 2A adenosine receptors
43. 1 adenosine antagonists: Structure-affinity profile of a series of 1,8-naphthyridine derivatives
44. 1 adenosine receptor antagonists
45. 1 receptor
46. 1,2,4-Triazolo[4,3-a]quinoxalin-1-one: A versatile tool for the synthesis of potent and selective adenosine receptor antagonists
47. Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists
48. Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists
49. XH-14 analogues as adenosine antagonists
50. 1-adenosine receptor
51. 1 receptor: Differential effects on agonist and antagonist binding
52. Selective amplification and cloning of four new members of the G protein-coupled receptor family
53. 2A receptors
54. 3 receptors: Pharmacological properties, species differences and receptor functions
55. 2A receptor
56. 2A receptors
57. Adenosine/dopamine interaction: Implications for the treatment of Parkinson's disease
58. 2A adenosine receptor antagonists - Future drugs for Parkinson's disease?
59. 2A adenosine receptor antagonists
60. 2A receptor
61. Alzheimer's disease: The tacrine legacy
62. Assessing the societal impact of acetylcholinesterase inhibitor therapies
63. 2A antagonist
64. 2A receptor antagonist
65. 2A-selective adenosine receptor antagonists
66. 2A-selective adenosine receptor antagonists
67. 2A receptors in the caudate-putamen
68. 2 receptor regulation in the rat dopamine-denervated striatum
69. 2A adenosine receptors
70. New substituted 9-alkylpurines as adenosine receptor ligands
71. 3 receptor subtypes
72. 2A adenosine antagonists
73. 2A adenosine antagonists
74. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors
75. 2A receptor system using positron emission tomography
76. 2A antagonists
77. 2A adenosine receptor
78. 2A adenosine receptors. Involvement of Glu13 and His278 in ligand binding and sodium modulation
79. Crystal structure of rhodopsin: A G protein-coupled receptor
80. 2A adenosine receptors by amiloride analogues and sodium ions
81. 2B adenosine receptors
82. Role of adenosine in asthma
83. 2B receptor
84. 2B adenosine receptors
85. 2B adenosine receptors
86. 2B adenosine receptors
87. 2B receptor
88. 2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity
89. 3 adenosine receptor
90. 3 adenosine receptor
91. 3 adenosine receptor variant
92. 3 adenosine receptors and stimulates mast cell degranulation
93. 3 adenosine receptor in determining tissue levels of cAMP and blood pressure: Studies in knock-out mice
94. 3 receptor expression and function in eosinophils
95. 3-adenosine receptors. Mediation of behavioural depressant effects
96. 3 adenosine receptor affects cell cycle progression and cell growth
97. 3 antagonists
98. 3 receptor
99. 3 adenosine receptor
100. 3 adenosine receptor antagonists
101. Interactions of flavonoids and other phytochemicals with adenosine receptors
102. Flavonoid derivatives as adenosine receptor antagonists: A comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model
103. 3 adenosine receptor antagonists
104. Structure-activity relationships and molecular modeling of 3,5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists
105. 3 adenosine receptor antagonists
106. 3 adenosine receptor antagonists
107. 3 adenosine receptor antagonists: Water-soluble 3,5-diacyl-1,2,4-trialkylpyridinium salts and their oxidative generation from dihydropyridine precursors
108. 3 adenosine receptor antagonists
109. 3 adenosine receptor antagonists
110. Targeting drugs to the brain by redox chemical delivery systems
111. 3 receptor subtype
112. 8 pyrazole nitrogen
113. Tumor angiogenesis - New drugs on the block
114. Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells
115. 'Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as example
116. 3 adenosine receptors
117. 3 adenosine receptors
118. 3 adenosine antagonists: Structural homology and receptor docking
119. 3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives
120. 3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds
121. The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family
122. 1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding
123. Further evidence that propentofylline (HWA 285) influences both adenosine receptors and adenosine transport
124. 2A antagonists with potent anti-cataleptic activity